September Awareness

September is the month of …

Alopecia Awareness –
Chiari Malformation Awareness –
Childhood Cancer Awareness –
Healthy Aging –
Hunger Action Month-
Infant Mortality Awareness –
Leukemia  & Lymphoma Awareness –
Ovarian Cancer Awareness –
Preparedness Month –
Prostate Cancer Awareness –
Thyroid Cancer Awareness –
The week of…

Suicide Prevention Week –
National Assisted Living Week –
The day of…

Labor Day (Sept 2)
National Service & Remembrance Day (Sept 11)
National Celiac Awareness Day (Sept 13) –
National HIV/AIDS Day and Aging Awareness Day (Sept 18) –
International Ozone Preservation Day (Sept 16) –
International Day of Peace (Sept 21) –
World Alzheimer’s Day (Sept 21) –
World Rabies Day (Sept 28) –
World Heart Day (Sept 29) –

CDC Public Health Grand Rounds

Maternal Immunization: Current Status and Future Directions

Wednesday, September 18, 2019
1:00 pm ET
Watch in person (Global Communications Center, Building 19), or live via webcast.


Pregnant women should routinely receive the Tdap (pertussis) vaccine and the influenza (flu) vaccine, as recommended by the Centers for Disease Control and Prevention (CDC). These vaccines have been shown to provide significant benefits to mother and baby.

Maternal Tdap vaccination helps protect infants who are at the greatest risk for developing pertussis (whooping cough) and its life-threatening complications. Flu vaccination during pregnancy is safe and helps protect babies from influenza for several months after birth. This is important because babies younger than 6 months of age are too young to get a flu vaccine. While Tdap and the flu vaccine are effective and safe, vaccination coverage of pregnant women remains too low.

Join us to learn about the burden of influenza and pertussis during pregnancy and among infants, the benefits of maternal immunization, and the development of new vaccines. Speakers will explore the barriers to immunizations and highlight Grady Memorial Hospital’s successes with maternal immunization.


Previous Grand Rounds

Learn More

Innovative Discoveries Series

Comparative Safety of Sulfonylureas in Type 2 Diabetes: Clinical Sequelae of KATP Blockade

Sulfonylureas remain important in the armamentarium of clinicians treating type 2 diabetes mellitus. Agents within this drug class are at least initially effective, generally well tolerated, and inexpensive. Yet, there are major concerns for serious hypoglycemia and untoward cardiovascular effects. To help inform second-line antidiabetic therapy prescribing decisions, it is critical to understand the safety of individual sulfonylureas. This talk will examine Dr. Leonard’s population-based pharmacoepidemiologic studies elucidating adverse effects of sulfonylureas, including investigations of: a) serious hypoglycemia potentiated by drug interactions; and b) sudden cardiac arrest.


Presented By:

Charles E. Leonard, PharmD, MSCE

Research Assistant Professor, Epidemiology, Department of Biostatistics, Epidemiology, and Informatics
Perleman School of Medicine, University of Pennsylvania

Special Government Employee, Food and Drug Administration


Free!  Lunch will be served!

This activity has been approved for AMA PRA Category 1 Credit.


Friday, September 27, 2019
Noon to 1 p.m.
In-person: Christiana Hospital, Room 1100
Online: Watch live at
Or join meeting ID 361095905 on the BlueJeans app on your smartphone or tablet

This activity has been approved for AMA PRA Category 1 Credit.

Upcoming Lectures:

October 11: Opioid Overdose Education with Naloxone Take Home in the Emergency Department

Statement on Vaccines

Vaccines Continue to be Tested and Proven Safe

American Academy of Pediatrics. (2017). American Academy of Pediatrics Emphasizes Safety and Importance of Vaccines. Retrieved from

Centers for Disease Control and Prevention. (2016). Infant Immunizations FAQs. Retrieved from

Institute of Medicine. (2004). Immunization Safety Review: Vaccines and Autism. Retrieved from

U.S. Food and Drug Administration. (2015).  Thimerosal in Vaccines: Questions and Answers. Retrieved from

In light of recent claims by politicians or appointees that vaccines are linked to autism, or are unsafe when administered according to the recommended schedule, or contain dangerous products like Thimerosal, the public health community and the Delaware Academy of Medicine/Delaware Public Health Association continue to come down on the side of science.

The Food and Drug Administration (FDA) Center for Biologics Evaluation and Research is responsible for regulating vaccines in the United States.  Before a vaccine can be licensed for public use, it must be tested for safety in the laboratory, in animals, and in human clinical trials.  Human clinical trials include looking for common adverse events in a few participants (phase 1), several hundred volunteers looking for local reactions and general side effects like fever (phase 2), and establishing the effectiveness of the vaccine and determining less common side effects with thousands of participants (phase 3).  If a vaccine is to be given at the same time as another vaccine, the two vaccines are tested together (FDA, 2015).  If a dangerous effect is found, that vaccine is not licensed for public use.

Vaccines are continuously monitored following licensure by the Vaccine Adverse Event Reporting System (VAERS), which is run by both the FDA and the Centers for Disease Control (CDC).  The VAERS is a national system that collects all reports of adverse events following vaccination.  Phase 4 clinical studies are also conducted to further evaluate the new vaccine, and population based studies are conducted through the use of databases like the Vaccine Safety Datalink (VSD) for the lifetime of the use of the vaccine (FDA, 2015).

The Institute of Medicine (IOM) Immunization Safety Review Committee “favors rejection of a causal relationship between thimerosal-containing vaccines and autism” (IOM, 2004).  Despite this finding, “all vaccines routinely recommended for children 6 years of age or younger and marketed in the U.S. contain no thimerosal or only trace amounts” (FDA, 2015).

“Infants and young children who follow immunization schedules that spread out shots – or leave out shots – are at risk of developing diseases during the time that shots are delayed” (CDC, 2016). Vaccines “keep communities healthy, and protect some of the most vulnerable in our society” (American Academy of Pediatrics, 2017).  The Delaware Academy of Medicine will continue to advocate for vaccines and vaccine use in the state of Delaware and the United States.